“TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.”
FDA Grants Clearance for Phase 1b/2 Trial of SNB-101 in SCLC
“The FDA has granted clearance to the investigational new drug application of SNB-101 in small cell lung cancer (SCLC) treatment. A phase 1b/2 clinical trial plans to evaluate SNB-101 in this patient population. This achievement follows the FDA’s orphan drug designation to SNB-101 in SCLC in 2023 and its fast track designation in 2024.”
Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality
“Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in eClinicalMedicine. The findings suggested that these areas need ongoing policy measures and research to further reduce mortality rates.”
Joint Study Aims To Use Simple Blood Test To Detect Lung Cancer
“Moffitt Cancer Center has joined forces with Cizzle Biotechnology to advance early-stage lung cancer detection. The UK diagnostics company has been focused identifying a new lung cancer biomarker, CIZ1B, through a simple blood sample.”
Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity
“Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with individuals of color and those living in rural areas of the country experiencing the worst outcomes.”
LUNGevity Issues Four RFAs in Support of the Lung Cancer Research Workforce
“WASHINGTON, Jan. 13, 2025 /PRNewswire/ — LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is excited to issue four Requests for Applications (RFAs) in their continued effort to improve outcomes for patients with lung cancer.”
Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds
“Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased recurrence risk in patients with early-stage lung adenocarcinoma, suggesting a potential role for more sensitive personalized genomic tests to guide treatment.”
Wildfire Smoke Exposure Heightens Lung Cancer Risks and Complicates Patient Outcomes
“Key Takeaways: Wildfire smoke contains PM2.5, linked to increased lung cancer risk and chronic health conditions. Firefighters face a 43% increased lung cancer mortality risk due to smoke exposure.”
OS Therapies’ HER2 drug prevented lung cancer from returning in a 3rd of patients
“OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune response against cancer cells expressing HER2. OS Therapies had been testing the drug in a phase 2b trial in 39 patients between the ages of 12 and 39.”
Lung cancer diagnoses in American women outpace men for first time
“Cancer incidence young and middle-aged women is rising, driven in part by a growing number of new lung cancer cases that are striking women more than men for the first time, per updated American Cancer Society statistics.”
Improved Radon Maps Can Help Prevent Lung Cancer in the U.S.
Radon exposure is the second leading cause of lung cancer deaths in the United States. The odorless, invisible gas is naturally released from soil, rocks, and water, and can build up in homes when it enters through cracks in the foundation. Increasing awareness and prevention of radon exposure have been goals of the Biden Cancer Moonshot initiative in recent years. In November, the White House convened a roundtable of radon researchers to share their expertise, including Longxiang Li, ScD, assistant professor of environmental health at Emory’s Rollins School of Public Health. Li shared insights from his efforts to update nationwide radon concentration maps, which were recently published in Proceedings of the National Academy of Sciences of the United States of America.”
FDA Targets Nicotine to Reduce Lung Cancer and Other Tobacco-Related Diseases
“On Wednesday, the FDA announced a proposed a rule that would significantly reduce nicotine levels in cigarettes and other combusted tobacco products, making them minimally or non-addictive, a groundbreaking move that could drastically reduce smoking-related illnesses and deaths in the US.”
American Lung Association Disappointed About Ruling in Graphic Warning Labels Case
“This week, U.S. District Judge J. Campbell Barker in Tyler, Texas, ruled in favor of tobacco industry plaintiffs that the U.S. Food and Drug Administration (FDA) cannot proceed with its rule to require graphic warning labels on cigarette packages until the legal challenge to the rule is resolved.”
